ABT vs PEP: How Abbott Laboratories and PepsiCo Compare (2026)

Same yardstick, side by side (as of July 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ABT and PEP share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ABT and PEP exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Abbott Laboratories is a global healthcare company headquartered in North Chicago, Illinois, that discovers, develops, manufactures, and sells health care products in more than 160 countries through four segments: Medical Devices, Diagnostic Products, Nutritional Products, and Established Pharmaceutical Products. Medical Devices, the largest segment at roughly $21.4 billion in 2025 revenue, includes the FreeStyle Libre family of continuous glucose monitors, structural heart products (Navitor, TriClip), electrophysiology systems (AVEIR leadless pacemaker), vascular devices, and heart-failure technologies. Diagnostics contributes roughly $8.9 billion, Nutrition roughly $8.5 billion (anchored by Similac infant formula and Ensure adult nutrition), and Established Pharmaceuticals roughly $5.5 billion in branded generics sold primarily in emerging markets.

Full ABT guide

PepsiCo is one of the world's largest food and beverage companies, generating roughly $19.4 billion in the first quarter of 2026 across a portfolio that spans Pepsi, Gatorade, Mountain Dew, Lay's, Doritos, Cheetos, Tostitos and Quaker. Its Frito-Lay snack arm controls more than 60% of the U.S. salty-snacks market and carries operating margins north of 40%, making convenient foods the company's profit engine, while its beverage unit holds the No. 2 spot in U.S. carbonated soft drinks (behind Coca-Cola) and leads sports drinks with Gatorade. Roughly half of revenue comes from foods and the business is spread across North America and fast-growing international markets.

Full PEP guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ABT drivers: FreeStyle Libre: A Platform, Not Just a Product; Cardiovascular and Electrophysiology Momentum.
• PEP drivers: Frito-Lay snack moat; Volume recovery and value pricing.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The most acute near-term risk is infant formula litigation: juries have delivered verdicts including a $53 million compensatory award in late March 2026 and a separately upheld $495 million verdict, with hundreds of additional NEC-related cases still pending, and a securities class action filed in 2026 adds a parallel legal exposure track targeting alleged investor misstatements. For PEP, pepsiCo faces several structural headwinds.

Pick ABT if you believe its drivers more; PEP if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ABT and PEP guides.

ABT. ABT's trailing GAAP P/E of roughly 26x sits below its own 3-year, 5-year, and 10-year historical averages, and is modestly above the Medical Devices and Instruments industry median of roughly 25x, suggesting the market has re-rated the stock from COVID-era growth-premium levels while still assigning a quality multiple. Revenue growth has remained consistently positive in the 5-7% range even as GAAP EPS was pressured in FY2025 by a year-over-year comparison that included elevated one-time items. The FY2026 adjusted EPS guidance of $5.38-$5.58 implies a forward adjusted P/E in the high-teens to low-twenties range at recent share prices, which analysts broadly describe as modestly discounted relative to fundamental fair value estimates.

PEP. PepsiCo grew Q1 2026 revenue about 8.5% year over year to roughly $19.4 billion with core EPS near $1.61, beating estimates and expanding operating margin to about 17%. At around $143 (July 2026) the stock sits roughly 15% below its February high near $171 and trades at about 16x forward earnings, below the S&P 500 average, while yielding close to 4%. The valuation reflects a market pricing in slow growth in exchange for defensive stability and reliable income.

Headline figures (approximate, 2026-06-27 (TTM through Q1 2026; share price data as of June 26, 2026)): ABT shows revenue (ttm) ~$45.1 billion, revenue (fy 2025) ~$44.3 billion (+5.7% YoY), net income (fy 2025) ~$6.5 billion, net profit margin (fy 2025) ~14.7%; PEP shows q1 2026 revenue ~$19.4B, q1 2026 core eps ~$1.61, market cap ~$195B, forward p/e ~16x.

ABT and PEP are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ABT and PEP exposure against your real portfolio. It is not an investment adviser.